论文部分内容阅读
目的观察替吉奥一线治疗老年进展期胃癌的近期有效性及安全性。方法 56例老年进展期胃癌患者随机分为两组:治疗组28例口服替吉奥胶囊40 mg/m2,Bid,d1~28,q5w;对照组28例口服卡培他滨片1250 mg/m2,Bid,d1~14,q3w;化疗3个周期后评价近期疗效及不良反应。结果 56例均可评价;治疗组和对照组的近期有效率(RR)分别为46.4%和42.9%,两组比较差异无显著性(P>0.05),但治疗组的不良反应及严重反应发生率均明显低于对照组(P<0.01)。结论替吉奥治疗老年进展期胃癌的疗效较好,不良反应轻,值得临床进一步研究应用。
Objective To observe the short-term effectiveness and safety of Tiagio in the treatment of advanced gastric cancer. Methods 56 cases of advanced gastric cancer were randomly divided into two groups: 28 cases in the treatment group received Ticagre’s capsule 40 mg / m 2, Bid, d 1 ~ 28, q 5 w; control group, 28 cases received capecitabine 1250 mg / m 2 , Bid, d1 ~ 14, q3w; evaluate the short-term curative effect and adverse reaction after 3 cycles of chemotherapy. Results All of the 56 cases were evaluable. The short-term effective rates (RR) of the treatment group and the control group were 46.4% and 42.9% respectively, with no significant difference between the two groups (P> 0.05). However, adverse reactions and serious reactions Rates were significantly lower than the control group (P <0.01). Conclusion Tigio treatment of elderly patients with advanced gastric cancer has good curative effect and light adverse reactions, which deserves further clinical application.